Literature DB >> 27590181

Kawasaki disease: etiopathogenesis and novel treatment strategies.

Shreya Agarwal1, Devendra K Agrawal1.   

Abstract

INTRODUCTION: Kawasaki disease is an acute febrile systemic vasculitis that predominantly occurs in children below five years of age. Its etiopathogenesis is still not clear, but it is thought to be a complex interplay of genetic factors, infections and immunity. Areas covered: This review article discusses in detail Kawasaki disease, with particular emphasis on the recent updates on its pathogenesis and upcoming alternate treatment options. Though self-limiting in many cases, it can lead to severe complications like coronary artery aneurysms and thrombo-embolic occlusions, and hence requires early diagnosis and urgent attention to avoid them. Intravenous immunoglobulin (IVIG) with or without aspirin has remained the sole treatment option for these cases, but 10-15% cases develop resistance to this treatment. Expert commentary: There is a need to develop additional treatment strategies for children with Kawasaki disease. Targeting different steps of pathogenesis could provide us with alternate therapeutic options.

Entities:  

Keywords:  Coronary artery aneurysm; Kawasaki disease; intravenous immunoglobulin; refractory Kawasaki disease; thrombo-embolic occlusion

Mesh:

Substances:

Year:  2016        PMID: 27590181      PMCID: PMC5542821          DOI: 10.1080/1744666X.2017.1232165

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  94 in total

1.  Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease.

Authors:  M Miura; H Ohki; S Yoshiba; H Ueda; A Sugaya; M Satoh; H Yamagishi
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

2.  Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease.

Authors:  Kee-Soo Ha; Jeehoo Lee; Gi Young Jang; JungHwa Lee; Kwang Chul Lee; Chang Sung Son; Joo Won Lee
Journal:  Am J Cardiol       Date:  2015-04-18       Impact factor: 2.778

Review 3.  Update on Kawasaki disease: epidemiology, aetiology and pathogenesis.

Authors:  Deane Yim; Nigel Curtis; Michael Cheung; David Burgner
Journal:  J Paediatr Child Health       Date:  2013-04-07       Impact factor: 1.954

Review 4.  Kawasaki disease: an evolving paradigm.

Authors:  Antonio Greco; Armando De Virgilio; Maria Ida Rizzo; Mario Tombolini; Andrea Gallo; Massimo Fusconi; Giovanni Ruoppolo; Giulio Pagliuca; Salvatore Martellucci; Marco de Vincentiis
Journal:  Autoimmun Rev       Date:  2015-04-13       Impact factor: 9.754

5.  Infliximab plus plasma exchange rescue therapy in Kawasaki disease.

Authors:  Kaori Sonoda; Masaaki Mori; Tatsunori Hokosaki; Shumpei Yokota
Journal:  J Pediatr       Date:  2014-02-20       Impact factor: 4.406

6.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal:  Lancet       Date:  2014-02-24       Impact factor: 79.321

7.  Bull's eye dermatoscopy pattern at bacillus Calmette-Guérin inoculation site correlates with systemic involvements in patients with Kawasaki disease.

Authors:  Han-Chi Tseng; Ji-Chen Ho; Mindy Ming-Huey Guo; Mao-Hung Lo; Kai-Sheng Hsieh; Wen-Chien Tsai; Ho-Chang Kuo; Chih-Hung Lee
Journal:  J Dermatol       Date:  2016-03-03       Impact factor: 4.005

Review 8.  Epidemiology of Kawasaki disease in Asia, Europe, and the United States.

Authors:  Ritei Uehara; Ermias D Belay
Journal:  J Epidemiol       Date:  2012-02-04       Impact factor: 3.211

9.  Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan.

Authors:  Y Nagao; C Urabe; H Nakamura; N Hatano
Journal:  Epidemiol Infect       Date:  2015-07-23       Impact factor: 2.451

10.  Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora.

Authors:  Kyung-Yil Lee; Ji-Whan Han; Joon-Sung Lee
Journal:  Med Hypotheses       Date:  2007-03-06       Impact factor: 1.538

View more
  36 in total

1.  [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].

Authors:  Xin Wang; Si-Lin Pan; Zhan-Hui DU; Zhi-Xian Ji; Gang Luo; Hong-Xiao Sun; Shu-Jing Ma
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

Review 2.  The Immunogenetics of Vasculitis.

Authors:  Fotini B Karassa; Eleftherios Pelechas; Georgios Zouzos
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Immunological imbalance in microcephalic children with congenital Zika virus syndrome.

Authors:  Amanda Costa Ayres Salmeron; Wallace Pitanga Bezerra; Rafaela Lúcia Lopes de Souza; Luanderson Cardoso Pereira; Lícia Maria do Nascimento; Anna Cláudia Calvielli Castelo Branco; Luiza Emilia Cavalcanti Simas; Valéria Azevedo de Almeida; Pedro Henrique de Souza Palmeira; Christiane Medeiros Bezerra; Paulo Marcos Matta Guedes; Maria Notomi Sato; Valéria Soraya de Farias Sales; Reginaldo Antônio de Oliveira Freitas Júnior; Tatjana de Souza Lima Keesen; Manuela Sales Lima Nascimento
Journal:  Med Microbiol Immunol       Date:  2022-07-20       Impact factor: 4.148

Review 4.  Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.

Authors:  M A Bordea; C Costache; A Grama; A I Florian; I Lupan; G Samasca; D Deleanu; P Makovicky; P Makovicky; K Rimarova
Journal:  Physiol Res       Date:  2022-01-19       Impact factor: 1.881

5.  TNF-α blockers for the treatment of Kawasaki disease in children.

Authors:  Noyuri Yamaji; Katharina da Silva Lopes; Tetsuo Shoda; Kazue Ishitsuka; Tohru Kobayashi; Erika Ota; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2019-08-16

6.  Diagnostic strategies for oral manifestations of infectious diseases.

Authors:  Qianming Chen; Zaiye Li; Xin Zeng
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-04-25

7.  Observation on the clinical effect of high-dose Intravenous Immunoglobulin combined with low-dose prednisone acetate in the treatment of patients with Kawasaki Disease.

Authors:  Hao Zhang; Mei-Ying Wang; Yong-Nan Teng; Xiao-Dan Wang; Hai-Tao Cao
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

8.  The Most Common Clinical Features of Kawasaki Disease Patients in King Abdulaziz Medical City.

Authors:  Khalid Talal Alghamdi; Rahaf Abdulmalik Waggass; Syed Sameer Aga; Abdulaziz Ahmed Alrohaili; Ali Hassan Alaidroos; Mohammed Dakhilallah Alghamdi; Mohannd Khalid Algamdi; Ashwaq Talal Alghamdi
Journal:  Cureus       Date:  2021-05-19

9.  CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Authors:  Yu Lun; Nozha Borjini; Noriko N Miura; Naohito Ohno; Nora G Singer; Feng Lin
Journal:  J Immunol       Date:  2021-06-07       Impact factor: 5.426

10.  Importance of blood pressure control in Kawasaki disease with expanded multiple giant coronary aneurysms with a 32 mm maximum diameter: a case report.

Authors:  Yuji Moritoh; Masahiro Kamada; Shinsaku Matsumoto; Koji Kido
Journal:  Eur Heart J Case Rep       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.